Paul Stoffels
Paul, Baron Stoffels (born 8 March 1962 in Turnhout, Belgium) is a Belgian MD, who studied medicine at the University of Hasselt and the University of Antwerp (UA). In addition he studied Infectious Diseases and Tropical Medicine at the Prince Leopold Institute of Tropical Medicine in Antwerp, Belgium. He is Chief Scientific Officier, Worldwide Chairman of Janssen pharmaceuticals and he is a member of the Johnson & Johnson Executive Committee.[1]
Career
Stoffels worked for four years as a physician and researcher of HIV/AIDS and tropical diseases in Africa, where he met Peter Piot. In 1991, he returned to Belgium and became the Head of Development for the HIV compounds at Janssen Pharmaceutica in Beerse, Belgium. In 1993 he was promoted to Director of Clinical Research and Development for Infectious Diseases and Dermatology. In 1997, he left Janssen Pharmaceutica and together with Rudi Pauwels co-founded the biotech companies Tibotec and Virco.
When Johnson & Johnson acquired Tibotec-Virco in April 2002, he became Company Group Chairman of the Global Virology Franchise at Johnson & Johnson and Chairman of Tibotec. Currently Stoffels is the Chief Scientific Officer at Johnson & Johnson, and is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide as well as leading teams across different sectors (CNS, pain, infectious disease, metabolism, cardiovascular disease, and primary care) to set the companywide innovation agenda.
In 2020, he received the Louis Pasteur Leadership Award in Public Health.[2]
See also
- Paul Janssen, founder of Janssen Pharmaceutica
References
- ^ "Paul Stoffels, M.D." Janssen. Retrieved 18 March 2020.
- ^ US, Pasteur Foundation. "Paul Stoffels, M.D., The Honorable Jane Hartley, and Janet Tobias Honored With 2020 Pasteur Foundation Awards". www.prnewswire.com. Retrieved 24 March 2020.
Sources
External links
.svg){kind=small}   | This article about a Belgian scientist is a stub. You can help Wikipedia by expanding it. |